Meyer‐michel Samama

Meyer‐michel Samama's AcademicInfluence.com Rankings

Meyer‐michel Samama

Medical

#1818

World Rank

#2194

Historical Rank

Hematology

#23

World Rank

#26

Historical Rank

Cardiology

#147

World Rank

#150

Historical Rank

Pharmacology

#172

World Rank

#211

Historical Rank

medical Degrees

Meyer‐michel Samama

Philosophy

#5429

World Rank

#8225

Historical Rank

Logic

#2715

World Rank

#3745

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Meyer‐michel Samama Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Meyer‐michel Samama's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. (1999) (1459)
Venous thromboembolism (VTE) in Europe (2007) (1348)
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (830)
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (725)
An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. (2000) (719)
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. (2004) (483)
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor (2010) (470)
Low molecular weight heparin in prevention of perioperative thrombosis. (1992) (381)
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility (2010) (354)
Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence) (2006) (344)
Familial Dysfibrinogenemia and Thrombophilia (1995) (309)
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (301)
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. (1996) (290)
Thrombosis and Pregnancy in Congenital Deficiencies in AT III, Protein C or Protein S: Study of 78 Women (1990) (283)
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. (2013) (269)
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study (2003) (249)
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls (2011) (248)
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. (1991) (233)
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (220)
Prognostic factors for retinal vein occlusion: prospective study of 175 cases. (1996) (201)
Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. (2001) (195)
Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. (1985) (191)
Prevention and treatment of venous thromboembolism--International Consensus Statement. (2013) (188)
Laboratory assessment of new anticoagulants (2011) (183)
Antithrombotic therapy for venous thromboembolic disease. (1998) (180)
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg (1988) (178)
Assays for Measuring Rivaroxaban: Their Suitability and Limitations (2010) (170)
Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). (2003) (167)
Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis (1988) (154)
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (148)
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. (2013) (148)
Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. (1993) (144)
Laboratory assessment of rivaroxaban: a review (2013) (140)
Comparative pharmacokinetics of LMWHs. (2000) (135)
The Thrombophilic State in Cancer Patients (2001) (133)
Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay (2005) (132)
Patients With Cancer (2013) (132)
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. (2003) (131)
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. (2011) (129)
Prevention and Treatment of Venous Thromboembolism (2013) (125)
In vitro aspirin resistance detected by PFA‐100TM closure time: pivotal role of plasma von Willebrand factor (2004) (124)
Congenital protein C deficiency and thrombotic disease in nine French families. (1984) (122)
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. (2005) (121)
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma (2010) (119)
Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. (1986) (118)
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. (1988) (116)
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent (2002) (105)
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. (1997) (101)
ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES (1987) (101)
Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery (1999) (98)
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. (1997) (94)
Laboratory diagnosis of the thrombophilic state in cancer patients. (1999) (92)
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life‐threatening hemorrhage (2002) (89)
Absence of In Vitro Cross-Reaction of Pentasaccharide with the Plasma Heparin-Dependent Factor of Twenty-Five Patients with Heparin-Associated Thrombocytopenia (1995) (88)
Contemporary laboratory monitoring of low molecular weight heparins. (1995) (85)
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study (2006) (81)
A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. (1994) (80)
Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. (1993) (79)
Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports. (1995) (79)
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. (1988) (73)
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. (2012) (70)
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation (2012) (70)
Pharmacokinetics of low molecular weight heparins. (1990) (68)
Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. (1986) (68)
Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients. (2008) (66)
Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. (1993) (65)
Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group. (1992) (62)
Persistent Heparin Induced Thrombocytopenia Despite Therapy with Low Molecular Weight Heparin (1984) (61)
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study (2013) (61)
Expression of a Paternal History of Premature Myocardial Infarction on Fibrinogen, Factor VIIC and PAI-1 in European Offspring - The EARS Study (1994) (61)
Factor VII activation and menopausal status. (1990) (60)
Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th New Antithrombotic Drugs : Antithrombotic (2012) (60)
The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. (1993) (60)
Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). (1994) (60)
An electronic tool for venous thromboembolism prevention in medical and surgical patients. (2006) (58)
Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis (1992) (55)
[New antithrombotic agents]. (1995) (55)
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation (2004) (54)
Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. (1986) (54)
Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays (2013) (53)
Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood (2004) (53)
Effects of long term administration of ticlopidine on platelet function and hemostatic variables. (1980) (52)
Evaluation of a method to assess red blood cell aggregation. (1989) (52)
Newer anticoagulants in 2009 (2009) (49)
Increased red blood cell aggregation in retinal vein occlusion (1990) (49)
Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. (1994) (49)
The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile (2006) (48)
The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor (2013) (48)
Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients (2007) (48)
Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice (1990) (47)
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma (2004) (47)
At III content and antithrombin in activity in oestrogen-progestogen and progestogen-only treated women. (1980) (46)
PL2‐49, a monoclonal antibody against glycoprotein IIb which is a platelet activator (1989) (45)
Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta- fibrin) (1987) (43)
FURTHER EVIDENCE THAT ACTIVATED FACTOR VII IS RELATED TO PLASMA LIPIDS (1985) (43)
Biochemistry and clinical pharmacology of new anticoagulant agents (2002) (43)
Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin). (1987) (43)
Screening for aspirin resistance in stable coronary artery patients by three different tests. (2007) (42)
Ex vivo reversal of the anticoagulant effects of edoxaban. (2014) (42)
Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post‐thrombotic treatment (1994) (42)
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. (2004) (41)
Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: A report of four patients (1991) (41)
Conformational change in fibrinogen induced by adsorption to a surface (1985) (41)
Monitoring plasma levels of factor Xa inhibitors: how, why and when? (2013) (38)
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. (1988) (38)
Parenteral Anticoagulants (2008) (38)
A European view on the North American fifth consensus on antithrombotic therapy. (2000) (37)
Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. (2012) (37)
Fibrinogen Troyes - Fibrinogen Metz (1972) (37)
Inherited thrombophilia and gestational venous thromboembolism. (2003) (35)
Prophylaxis of venous thromboembolism in medical patients (2004) (35)
Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy. (2012) (35)
Constitutional Thrombocytopathy with Subnormal Response to Thromboxane A2 (1981) (35)
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile (2004) (34)
Do new oral anticoagulants require laboratory monitoring? The clinician point of view. (2012) (33)
Does ambulation modify venous thromboembolism risk in acutely ill medical patients? (2010) (33)
The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. (2005) (32)
Pregnancy‐associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone (2003) (32)
Synthetic direct and indirect factor Xa inhibitors. (2002) (32)
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely III Medical Patients (2000) (31)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. (1993) (31)
Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment (2011) (31)
[Plasminogen determination, using a chromogenic tripeptidic substrate (author's transl)]. (1976) (31)
On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life‐threatening haemorrhage: focus on prothrombin activation (2002) (30)
Heterogeneity of synthetic factor Xa inhibitors. (2005) (30)
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency (1993) (30)
Familial and constitutional bleeding disorder due to platelet cyclo‐oxygenase deficiency (1983) (28)
Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. (1985) (28)
Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. (1996) (28)
Calcium rise in human platelets elicited by anti-CD9 and -CD41 murine monoclonal antibodies. (1989) (28)
Applying risk assessment models in general surgery: effective risk stratification. (1999) (28)
Familial dysfibrinogenemia and thrombophilia. Structural defects and impaired fibrinolysis (1994) (27)
Acute Ischemic Stroke and Heparin Treatments (1997) (27)
Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion. (1997) (26)
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. (2010) (26)
In vitro effect on heptest® of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities (1990) (26)
Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study (2013) (26)
A fatal low‐molecular‐weight heparin‐associated thrombocytopenia after hip surgery: possible usefulness of PF4‐heparin ELISA test (1996) (25)
Double-Blind Trial of the Efficacy of Troxerutin in Chronic Venous Insufficiency (1994) (24)
Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis. (1988) (24)
In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. (2008) (24)
The significance of endothelial heterogeneity in thrombosis and hemostasis. (2010) (24)
Interactions of anticoagulant insoluble modified polystyrene resins with plasmatic proteins. (1982) (23)
Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart". (1999) (22)
Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin. (1985) (22)
Pharmacology and laboratory testing of the oral Xa inhibitors. (2014) (22)
[Randiomized trial of a new platelet anti-aggregant agent: ticlopidine]. (1977) (21)
Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. (1998) (21)
Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin (2009) (21)
Fibrinogen Haifa: Fibrinogen Variant with Absence of Protective Effect of Calcium on Plasmin Degradation of Gamma Chains (1987) (20)
Pharmacokinetics of low molecular weight heparins. (1988) (20)
Age-related changes in factor VII activation in healthy women. (1988) (20)
Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. (1996) (19)
Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. (1988) (19)
An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients (2006) (19)
In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. (1990) (18)
Risk assessment models for thromboprophylaxis of medical patients. (2012) (18)
[The new heparins]. (1986) (18)
Study of acquired dysfibrinogenaemia in liver disease. (1980) (18)
Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin. (1988) (18)
Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes (2008) (18)
The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. (1990) (17)
PREGNANCY AND CONGENITAL DEFICIENCY IN ANTITHROMBIN III OR PROTEIN C (1987) (17)
Clinical Studies with Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism (1989) (17)
DETECTION OF FIBRINOGEN ABNORMALITY IN DYSFIBRINOGENEMIA SPECIAL REPORT ON FIBRINOGEN METZ CHARACTERIZED BY AN AMINO ACID SUBSTITUTION LOCATED AT THE PEPTIDE BOND CLEAVED BY THROMBIN. (1982) (17)
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina * (2003) (17)
Severe Protein C Deficiency in Congenital Thrombotic Disease – Description of an Immunoenzymological Assay for Protein C Determination (1985) (17)
Antiplatelet Effects of the Addition of Acetylsalicylic Acid 40 Mg Daily to Ticlopidine in Human Healthy Volunteers (1997) (17)
The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. (2000) (17)
Clinical Aspects and Laboratory Problems in Hereditary Thrombophilia (1999) (17)
Inferior Vena Cava Filters (2013) (17)
Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. (2002) (16)
Pathobiology of thrombin in acute coronary syndromes. (1998) (16)
Relationship between plasminogen activator inhibitor activity and menopausal status (1990) (16)
New heparin-like insoluble materials: Part I (2006) (16)
Gynecology and Obstetrics (2013) (15)
Spontaneous platelet aggregation in heparin-treated patients. (1984) (15)
Immunochemical differentiation of fibrinogen, fragment D or E, and cross-linked fibrin degradation products using monoclonal antibodies (1983) (15)
Clot-promoting and platelet-aggregating effects of fatty acids. (1973) (15)
Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin (1982) (15)
Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. (1990) (15)
DOXACURIUM (BW 938) VERSUS PANCURONIUM IN PATIENTS UNDERGOING ABDOMINAL AORTIC SURGERYEFFECTS ON HEMODYNAMICS AND LV FUNCTION (1988) (15)
INCREASED SENSITIVITY OF PLATELETS TO ADRENALINE IN HUMAN MYOTONIC DYSTROPHY (1975) (15)
Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. (1994) (15)
Prevention of venous thromboembolism after surgery: A review of enoxaparin (1992) (14)
Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor II. (1986) (14)
The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia (2001) (14)
Effect of Standard Heparin and a Low Molecular Weight Heparin on Thrombolytic and Fibrinolytic Activity of Single-Chain Urokinase Plasminogen Activator In Vitro (1989) (14)
Rapid Aequorin Loading into Platelets in the Presence of DMSO - Characteristics of the Responses (Changes in Light Transmission and in Calcium) to Various Agonists (1991) (14)
CONGENITAL FACTOR VII DEFICIENCY AND CEREBROVASCULAR STROKE (1985) (14)
Hypofibrinolysis and venous thrombosis (1992) (14)
The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement (2000) (13)
Factor VII activation and oral contraceptives. (1993) (13)
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients (2013) (13)
Human platelet fibrinogen: a protein different from plasma fibrinogen. (1976) (13)
Red cell aggregability increases with the severity of venous insufficiency. (1995) (12)
Prevention of thromboembolic disease in general surgery with enoxaparin. (1989) (12)
Urokinase I and II Activity (1978) (12)
[MASSIVE THROMBOSIS OF THE VESSELS OF AN EXTREMITY DURING A CONGENITAL HYPOFIBRINEMIA]. (1964) (12)
Vitamin K metabolism in a patient resistant to vitamin K antagonists. (1997) (12)
Management of Pregnancy in Women with Thrombophilia (1999) (12)
Intra-Coronary Thrombolysis with Streptokinase or Lys-Plasminogen/Urokinase in Acute Myocardial Infarction: Effects on Recanalization and Blood Fibrinolysis (1983) (12)
Laboratory monitoring of oral anticoagulant therapy. (1994) (12)
Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane). (1990) (12)
Defective thrombolysis due to collagen incorporation in fibrin clots. (1988) (12)
Heparin- and streptokinase-dependent platelet-activating immunoglobulin G: mechanism and diagnosis. (1995) (11)
[Increase of erythrocyte aggregation in retinal vein occlusion]. (1990) (11)
[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time]. (2000) (11)
Damad study research group : Effect of age on ADP-induced platelet aggregation in diabetic and non-diabetic subjects (1981) (11)
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians]. (2009) (11)
Treatment for Patients With Cancer (2013) (10)
Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis (1994) (10)
Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe) (1985) (10)
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. (2002) (10)
Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery. (1991) (10)
Anticoagulant drugs: an update (2004) (10)
The Need for Standardization of Low Molecular Weight Heparin (LMWH) (1986) (10)
TREATMENT OF POST CAROTID ENDARTERECTOMY HYPERTENSION WITH NIFEDIPINE: EFFECTS ON HEMODYNAMICS AND MIXED VENOUS OXYGEN SATURATION (1986) (10)
Suitability of Chromogenic Anti-Factor Xa Methods to Measure Rivaroxaban in Human Plasma (2009) (10)
Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease (2009) (10)
Structure Abnormality Of Fibrinogen Metz And Its Relationship To The Clotting Defect (1981) (10)
[Is Behçet's disease associated with characteristic abnormalities of coagulation and fibrinolysis? Apropos of 70 case reports]. (1988) (10)
Laboratory Techniques in Thrombosis – A Manual, 2nd Revised Edition of ECAT Assay Procedures (2000) (9)
Analysis of a fibrin formation abnormality in a case of multiple myeloma. (2009) (9)
Standard measurement of clot-bound thrombin by using a chromogenic substrate for thrombin. (2004) (9)
The fibrinolytic system in patients with congenital protein C deficiency. (1984) (9)
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? (2009) (9)
Laboratory monitoring of unfractionated heparin treatment. (1995) (9)
The Amidolytic Activity of the SK-Plasminogen Complex Is Enhanced by a Potentiator which Is Generated in the Presence of Vascular Plasminogen Activator - Role of Fibrin Degradation Products (1982) (9)
Coronary Stenting in a Hemophilic Patient (1997) (9)
Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin. (1978) (9)
[Dermatan sulfate and the prevention of experimental venous thrombosis]. (1989) (8)
Prothrombotic states in retinal artery and vein occlusions (2002) (8)
Thrombin-Antithrombin III Complexes for the Detection of Postoperative Hypercoagulable State in Surgical Patients Receiving Heparin Prophylaxis (1989) (8)
A comparative study of recombinant hirudin and standard heparin in the Wessler model. (1992) (8)
Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII. (1999) (8)
[Platelets and diabetes]. (1982) (8)
Thrombolytic Therapy: Future Issues (1995) (8)
INTRAVENOUS LABETALOL FOR TREATMENT OF POSTOPERATIVE HYPERTENSIONEFFECTS ON HEMODYNAMICS AND LEFT VENTRICULAR FUNCTION (1988) (7)
Markers of fibrinogen derivatives used in clinical investigation. (1985) (7)
Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction. (1987) (7)
Thrombolytic properties of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (scu-PA) in vitro: Absence of synergy as demonstrated by two quantitative analytical methods (1989) (7)
Ultraviolet irradiation of platelet concentrates: In Vitro and In Vivo preclinical evaluation (1990) (7)
Is factor VII activation in pregnant women relevant to fetal growth retardation? (1987) (7)
Diagnosis and Anticoagulant Treatment * (2013) (7)
On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma (2003) (7)
Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation (2008) (7)
Original Article: Streptokinase Modifies in Vitro Platelet Aggregation by Two Mechanisms: Reduced Aggregation due to Fibrinogenolysis and Enhanced Aggregation via an Immunological Reaction. (1995) (7)
Plasma beta-thromboglobulin in patients with valvular heart disease with or without valve replacement: relationship with thromboembolic accidents. (1984) (7)
Deep vein thrombosis of inferior limbs: are thrombolytic agents superior to heparin? (1987) (6)
In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractionated heparin (2003) (6)
Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents (2001) (6)
Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin (2000) (6)
Study of platelet diameter distribution in patients with valvular heart disease and with prosthetic heart valve replacement. (1981) (6)
Ultrastructure of a model of thrombogenesis induced by mechanical injury. (1981) (6)
[Prevention of venous thromboembolic disease]. (1996) (6)
In vitro effect of melagatran and lepirudin on clot-bound thrombin. (2003) (6)
Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels (2011) (6)
Low molecular weight heparins (1986) (6)
Medical patients. (2013) (6)
Anticoagulation: The Old and the New (1998) (6)
[Malignant atrophic papulosis with insufficiency of blood fibrinolysis]. (1982) (6)
[Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin]. (1996) (6)
Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures. (1991) (6)
[Venous thromboses associated with a constitutional deficiency of protein C. 3 cases]. (1983) (5)
Introduction - Uncharted territories in thrombosis care: Expanding into new areas (2002) (5)
[THE ALDRICH SYNDROME (FAMILIAL THROMBOPENIC PURPURA, ECZEMA, RECURRING INFECTIONS)]. (1963) (5)
[The new heparins]. (1986) (5)
Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. (1998) (5)
[Therapeutic indications of low molecular weight heparins]. (1991) (5)
Compared activity of human, rat and rabbit plasma tissue factor pathway inhibitors. (1993) (5)
Streptokinase and APSAC Inhibit Platelet Aggregation In Vitro by Fibrinogenolysis: Effect of Plasma Fibrinogen Degradation Products X and E (1995) (5)
Discriminant study of platelet volume indices in the etiological diagnosis of thrombocytopenia. (1984) (5)
On The Mechanism Of Inhibition Of Factor Viia By Synthetic Pentasaccharide, Low‐Molecular‐Weight Heparins And Unfractionated Heparin (2000) (5)
Evaluation of the antifactor XA chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls (2012) (5)
Study of 10 cases of congenital dysfibrinogenemia: clinical and molecular biological aspects (1985) (5)
New Data on the Pharmacology of Heparin and Low Molecular Weight Heparins (2012) (4)
Specific Anti-Xa Activity of LMWH (Kabi 2165, CY216 PK 10169) Against the First International Standard of LMWH: A Collaborative Study (1990) (4)
The heparin management test: a new device for monitoring anticoagulation during coronary intervention. (1999) (4)
Role of Trisodium Citrate in the Unclottability by Thrombin of Fibrinogen Metz (1975) (4)
Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients. (1984) (4)
[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate]. (2011) (4)
Does Increased Platelet Aggregation Have a Prognostic Value in the Deterioration of Background Diabetic Retinopathy? (1990) (4)
Influence of human ceruloplasmin on the aggregation of human platelets by adenosine diphosphate. (1974) (4)
Thrombolytic agents and treatments. (1987) (4)
[Platelets and atherosclerosis]. (1973) (4)
Coagulation Assays in Patients with New Oral Anticoagulants (NOACs): Why? When? (2013) (4)
Characterization of an anti-IIb/IIIa monoclonal antibody which is a platelet activator. (1988) (4)
Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro. (1991) (4)
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis]. (1982) (4)
[Hereditary protein S deficiency and recurrent venous thrombosis. Study of a family]. (1987) (4)
Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays (2008) (4)
Prevention of postoperative thromboembolism in general surgery with enoxaparin. (1994) (4)
Effects of saturated and unsaturated fatty acids on blood platelet aggregation in vitro and after injection into rabbits. (1972) (4)
Treatment of deep vein thrombosis (DVT) with low molecular weight heparins (LMWH). (1992) (4)
[Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients]. (2005) (4)
Degradation of fibrinogen by tissue plasminogen activator. Consequences for fibrin polymerization. (1990) (4)
51. The global fibrinolytic capacity (GFC), a promising method for hypofibrinolytic state detection in thrombotic diseases (1998) (4)
Effect of age on ADP-induced platelet aggregation in diabetic and non-diabetic subjects. (1981) (4)
From pharmacologic studies to the improvement of thromboprophylaxis (2003) (3)
[THE ROLE OF EPSILON-AMINOCAPROIC ACID IN FIBRINOLYTIC STATES]. (1964) (3)
[Hemorrhagic accidents of the new oral anticoagulants and coagulation assays]. (2013) (3)
[DISSOCIATED EFFECTS OF A NEW ANTIFIBRINOLYTIC AGENT (EPSILON-AMINOCAPROIC ACID) INJECTED "IN VIVO", ON "IN VITRO" FIBRINOLYSIS TESTS]. (1963) (3)
[Advances and perspectives in the prevention of venous thromboembolic disease]. (2001) (3)
[Anomalies of platelet aggregation during Waldenström's disease. (Apropos of 3 cases)]. (1966) (3)
[Apropos of 6 cases of Glanzmann's thrombasthenia. The value of thrombodynamographic study]. (1961) (3)
[Severe thrombocytopenia with pulmonary embolism and consumption coagulopathy during treatment with tedelparin]. (1991) (3)
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. (2014) (3)
[Protein C and its clinical implications]. (1985) (3)
Evaluation of the Anti-Factor Xa Chromogenic Assay for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls (2010) (3)
ADMINISTRATION OF TICLOPIDINE IMPEDES ADP-INDUCED ACTIVATION BUT DOES NOT INDUCE A THROMBASTHENIC STATE (1987) (3)
[How to provide practical treatment for ambulatory patients with deep venous thrombosis]. (1999) (3)
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM.International Consensus Statement. Guidelines compiled in accordance with the scientific evidence (2006) (3)
Platelet and red-cell fragments in thrombocytopenia. (1978) (3)
[The treatment of deep venous thrombosis with low-molecular-weight heparin]. (1995) (3)
In spite of elevated plasma fibrinogen, red blood cell aggregation is not increased in smokers (1992) (3)
[Erythrocyte aggregation and retinal vein occlusion. Preliminary data for a randomized study on the efficacy of anti-erythrocyte aggregation (troxerutin) in retinal vein occlusion]. (1989) (3)
Fibrinogen and platelet aggregation. Role of the glycopeptidic part and of the fibrinopeptide B. Description of a new technique of fibrinoglycopeptide isolation. (1978) (3)
Haemorrhagic aspects of thrombolytic therapy. (1990) (3)
Cost-Effectiveness of Prevention and Treatment of VTE (2013) (3)
Antithrombin III in Contraceptive Treatments with Oestroprogestagens or Progestagen -Only Pills (1979) (3)
Role of fibrin polymerization in fibrinolysis: Comparison between polymerisable and unpolymerisable fibrins in the potentiating effect of plasminogen activation by tissue-type plasminogen activator (tpA) (1986) (2)
[Low molecular weight heparin in unstable angina]. (1996) (2)
[Anti-streptokinase antibodies]. (1997) (2)
General, Vascular, Bariatric, and Plastic Surgical Patients (2013) (2)
[Increase in platelet sensitivity to adrenaline in Steinert's disease]. (1977) (2)
A New Fibrinogen Variant With Abnormal Gamma Chain : Fibrinogen Haifa (1981) (2)
Pro- and anti-angiogenic agents. (2012) (2)
HYPERCOAGULABLE STATE IN MULTIPLE MYELOMA PATIENTS TREATED OR NOT WITH THALIDOMIDE (2007) (2)
Platelet-associated fibrinogen: Conformational change of fibrinogen induced by its adsorption to platelet-surface (1986) (2)
Measuring rivaroxaban pharmacodynamics: prothrombinase-induced clotting time (PiCT ® ) and Heptest ® (2008) (2)
[A century of progress. From biology to antithrombotic agents]. (2001) (2)
[Prevention of postoperative thromboembolic complications]. (1994) (2)
Assessment of treatment strategy in high-risk surgical patients. (2000) (2)
[Coagulation and extracorporeal circulation with deep hypothermia]. (1962) (2)
[Perioperative use of antithrombotic agents: recommendations of the American College of Chest Physicians (ACCP) and the French Superior Health Authority (HAS)]. (2010) (2)
Clinical Thrombosis (2019) (2)
Interindividual variability of in vitro response to anticoagulants. (2011) (2)
[Thrombolytic agents and acute pulmonary emboli. Study of 28 cases treated by streptokinase or urokinase-heparin]. (1978) (2)
[Current biological surveillance of oral anticoagulant treatment]. (1995) (2)
BINDING OF CITRATE TO NORMAL FIBRINOGEN AND TO METZ FIBRINOGEN (1982) (2)
[Congenital and familial dysfibrinogenemia without hemorrhagic tendancy]. (1969) (2)
Combined Modalities in Surgical Patients (2013) (2)
LOW MOLECULAR WEIGHT HEPARIN (Enoxaparin) COMPARED WITH UNFRACTIONATED HEPARIN THRICE DAILY IN PREVENTION OF POSTOPERATIVE THROMBOSIS. A RANDOMIZED MULTICENTRE TRIAL (1987) (2)
[Thrombolysis by streptokinase (experimental and clinical study)]. (1969) (2)
[Thrombotic thrombopenic purpura associated with Hodgkin's disease]. (1983) (2)
Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model (1998) (2)
[Non-VKA oral anticoagulants: an update for the clinical biologists]. (2015) (2)
[Fatal fibrinolysis in the course of a portocaval anastomosis for cirrhosis complicated by recurring hematemesis]. (1959) (2)
[Fibrin formation disorders. Technic of evaluation of the first stage]. (1972) (2)
[Deep venous thrombosis following laparoscopic cholecystectomy]. (1994) (2)
Surgical thrombectomy. (2013) (2)
Choice of low molecular weight heparins (2003) (2)
Standardization of platelet counts--problems and pitfalls. (2009) (2)
COMPARISON BETWEEN THE POTENTIATING EFFECT INDUCED BY FIBRIN(OGEN) DERIVATIVES ON PLASMINOGEN ACTIVATION INDUCED BY EITHER STREPTOKINASE OR TISSUE PLASMINOGEN-ACTIVATOR (1984) (2)
Study of the interaction between plasminogen and fibrinogen degradation products using immunoenzymological assay (1985) (2)
[FIBRINOLYTIC HYPERACTIVITY DURING CARDIAC SURGERY WITH EXTRACORPOREAL CIRCULATION. STUDY BASED ON 280 OPERATIONS]. (1963) (2)
Prevention of thromboembolic disease in general surgery with clexane (enoxaparin). (1991) (2)
[FIBRINOLYSIS AND EPSILON-AMINOCAPROIC ACID]. (1964) (2)
Studies on the structure of the fragment D moiety of abnormal fibrinogens: influence of calcium ions. (1978) (2)
[Lipolytic and anticoagulant activities of heparin and one of its low molecular weight derivatives]. (1987) (2)
Overall study of the in vitro plasma clotting system in an invertebrate, Liocarcinus puber (Crustacea Decapoda): considerations on the structure of the Crustacea plasma fibrinogen in relation to evolution. (1989) (2)
[The treatment of acute arterial obliterations with streptokinase]. (1967) (2)
[Congenital dysfibrinogenemia]. (1973) (2)
ABNORMAL FACTOR-VIII-RELATED ANTIGEN, VON WILLEBRAND DISEASE, AND PREGNANCY (1976) (2)
[Pregnancy-associated venous thrombosis in women with hereditary heterozygous factor V Leiden and/or factor II gene mutations]. (2004) (2)
Inhibition of In Vitro Thrombin Generation: Another Parameter Reinforcing the LMWH Heterogeneity. (2005) (2)
[Heparin in the treatment and secondary prevention of myocardial infarction. A critical review of the main trials]. (1991) (1)
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress]. (2012) (1)
[Hemagglutination inhibition (Merskey's test) in consumption coagulopathies. Apropos of 101 patients]. (1971) (1)
[Effects of thrombolysis on platelets and coagulation]. (1995) (1)
[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems]. (2010) (1)
Thrombosis: A Multidisciplinary Approach (2019) (1)
The Problem and the Need for Prevention (2013) (1)
Orthopedic Surgery and Trauma (2013) (1)
Prophylaxis of venous thromboembolism in acute medical patients with enoxaparin An international, randomized, double-blind, placebo-controlled trial (2000) (1)
[Erythrocyte aggregation in vascular disease. Influence++ of hypertension]. (1991) (1)
What Is The Best Time Sampling For The Two Direct Oral Anticoagulants, Dabigatran and Rivaroxaban? (2013) (1)
[Study of coagulation and hemostasis in 74 cases of cirrhosis]. (1960) (1)
Platelest counting: visual, electronic and fully automated optical methods. (1972) (1)
[A specific marker of thrombolysis: DDE complex]. (1987) (1)
[Thrombogenicity of biomaterials in cardiovascular surgery. Methods for improving the thrombogenicity of cardiovascular prostheses]. (1997) (1)
Evaluation of a method to assess plasma viscosity: the falling ball viscometer (1994) (1)
[Monitoring of treatment with vitamin K antagonists: a plea for "INR" (International Normalized Ratio)]. (1990) (1)
[Platelet volume in essential thrombopenia]. (1978) (1)
Physiology and Basic Investigation of Blood Coagulation (2019) (1)
Effect of venous occlusion on fibrinolysis before and after delivery. (1972) (1)
[Problems posed by the treatment of deep venous thrombosis in patients with a coagulopathy]. (1988) (1)
Lowmolecular weight heparin inprevention ofperioperative thrombosis (1992) (1)
[FIBRINOLYTIC HYPERACTIVITY IN 280 OPEN-HEART SURGERY PATIENTS. CLINICAL CORRELATIONS AND THERAPEUTIC RESULTS]. (1963) (1)
Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets. (1997) (1)
PO-73 Prevalence of cancer and congenital thrombophilia in 435 patients with acute venous thromboembolism (VTE) (2007) (1)
[Effect of a new cerebral vasodilator agent, viquidil, on the aggregation of blood platelets]. (1972) (1)
[Volume distribution studies on the platelet populations (author's transl)]. (1977) (1)
[Cataclysmic fibrinolytic complications observed during open-heart surgery]. (1961) (1)
[IMPORTANCE OF BLOOD LEVELS OF FIBRIN IN THE INTERPRETATION OF THE MAXIMUM AMPLITUDE OF THROMBODYNOGRAMS]. (1963) (1)
Research on the mechanism of synthetic thrombolytic agents. (1972) (1)
The Significance of Several Coagulation Tests in the Evaluation of the Risk of Bleeding (1984) (1)
A critical appraisal of the clinical efficiency of anti-platelet drugs. (1986) (1)
[New anticoagulants: mechanism of action and therapeutic targets]. (2005) (1)
[Thrombodynamography in hemorrhagic syndromes]. (1959) (1)
THROMBOSE VEINEUSE PROFONDE AU DECOURS D'UNE CHOLECYSTECTOMIE PAR LAPAROSCOPIE (1994) (1)
Reverting Rivaroxaban Effect By Activated Factor X: Assessment Using Thrombin Generation Assay (2014) (1)
Determination of fibrinogen degradation products using antifibrinogen serum and anti-fragment E serum (1973) (1)
IS INHALED NITRIC OXIDE ABLE TO REVERSE ALMITRINE-INDUCED PULMONARY HYPERTENSION IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME? (1994) (1)
Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Drug (2002) (1)
Key Questions to be Answered (2013) (1)
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study (2004) (1)
[Thrombodynamography (thromboelastography). Its present place in clinical practice]. (1960) (1)
[Thrombolytic treatment of subacute and chronic pulmonary embolism]. (1977) (1)
Fibrinolytic Activity and Venous Stasis (1970) (1)
[Drug-induced hemolysis]. (1968) (1)
Abnormalities in Fibrin Formation in Hepatic Disease. Consequences of Acquired Dysfibrinogenemia on Fibrin Formation and on Platelet Aggregation Cofactor Activity (1979) (1)
[Protein C deficiency and thromboembolic risk]. (1986) (1)
[ACTION OF EPSILON-AMINO CAPROIC ACID ON BLEEDING IN URINARY SURGERY]. (1963) (1)
EFFECT OF ASPIRIN AND ASPIRIN COMBINED WITH DIPYRIDAMOLE IN EARLY DIABETIC RETINOPATHY (1987) (1)
PHARMACOKINETICS OF EN0XAPARIN AFTER SINGLE SUBCUTANEOUS ADMINISTRATION OF INCREASING DOSES (20 UP TO 80 MG) TO HEALTHY VOLUNTEERS (1987) (1)
Effects of rivaroxaban and fondaparinux on clotting assays (2008) (1)
Tumour necrosis factor α stimulates the production of pro-urokinase from the A549 lung carcinoma cell line (1990) (1)
[Sclerotherapy of varices and protein C deficiency]. (1986) (1)
[There are low-molecular weight heparin-induced thrombocytopenia and of course you must have "met" some...]. (2003) (1)
Thrombolytic Therapy (2013) (1)
[The biological exploration of fibrinolysis]. (1962) (1)
[New antitoagulants]. (2007) (1)
Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities. (1986) (1)
[Treatment of deep venous thromboses with heparin. Therapeutic management and biological monitoring]. (1986) (1)
[Platelet collection by apheresis with reduced use of citrate: quantitative and qualitative evaluation of three protocols]. (1995) (1)
Study of coagulation fibrinolysis balance inhuman hyperlipidemia = contribution of factor VIIa in extrinsic hypercoagulability (1994) (1)
[Study of variability in response to aspirin and clopidogrel: clinical and/or biological resistance?]. (2009) (1)
Critical Care Medical Patients (2013) (1)
[Prevention of thromboembolism in digestive and abdominal surgery. New heparins]. (1992) (1)
Prevention and Treatment of Venous and Arterial Thrombosis in Patients with Specific Conditions: Diabetes, Hypercoagulable States, Pregnancy, and Renal Insufficiency (2012) (1)
312 Cultured A549 lung carcinoma cells release sc-UPA (1988) (1)
Laboratory control of thrombolytic treatment of myocardial infarction with rt-PA (1993) (1)
Heritable Thrombophilia and Pregnancy Associated Thrombosis. (2002) (1)
Red blood cell aggregation is increased in retinal vein occlusion (1990) (1)
[Thrombodynamographic abnormalities in myeloid leukemia]. (1958) (1)
[Study of fibrinolytic and platelet activities in diabetics]. (1967) (1)
[Cutaneous necrosis of the breast: a complication of oral anticoagulant treatment]. (1983) (1)
Anti-Factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicentre field trial (2012) (1)
New heparin-like insoluble materials: Part II (2006) (1)
[Technics and results of systematic peroperative surveillance of coagulation in open-heart surgery]. (1962) (1)
EVALUATION OF A NEW FUNCTIONAL CLOTTING ASSAY FOR THE MONITORING OF HEPARIN AND HEPARINOID ANTICOAGULANTS BASED ON THROMBIN AND/OR FACTOR XA INHIBITION WITH CLINICAL PATIENT PLASMAS AT THREE UNIVERSITY MEDICAL CENTERS (2007) (1)
[Mechanism of activation of the fibrinolytic system in cardiac surgery with extracorporeal circulation and deep hypothermia]. (1962) (1)
[Effects of progestatin on glucido-lipid metabolism and coagulation]. (1981) (1)
[On the physical interpretation of thrombelastographic pictures]. (1963) (1)
[Staphylokinase and its mutants: a new generation of thrombolytic agents]. (1998) (1)
Effect of Argatroban versus Recombinant Hirudin on Tissue-Factor-Mediated Thrombin Generation: An in Vitro Study (2008) (1)
Risk Factors for Thrombosis and Bleedings Prevention of Arterial and Venous Thrombosis Treatment of VTE and Adverse Reactions (1999) (1)
[HEMATOLOGIC CHANGES OBSERVED AFTER SPLENECTOMY]. (1964) (1)
Proceedings of the second International Conference on Synthetic Fibrinolytic-Thrombolytic Agents (1975) (0)
[Critical study of the in vitro and in vivo effect of pyridinol carbamate on platelet adhesiveness and aggregation]. (1975) (0)
Subject Index, Vol. 23, 1993 (1993) (0)
[Medical treatment of retinal venous occlusions with a new defibrinating agent (Defibrase). Preliminary study]. (1982) (0)
Letter: Abnormal factor-viii-related antigen, von Willebrand disease, and pregnancy. (1976) (0)
STUDIES ON THE MECHANISM OF THE ANTITHROMBOTIC ACTION OF A CHEMICALLY SYNTHESIZED HEPARIN PENTASACCHARIDE (1987) (0)
The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM. (2008) (0)
[Pharmacology of anti-platelet agents]. (1983) (0)
C0551: Homozygous Protein C Deficiency with Late Clinical Onset. Long-Term Follow-Up in 4 Patients (2014) (0)
[Utilization in cardiology of synthetic antiocoagulants with rapid and semiprolonged action]. (1960) (0)
Comparison of the effects of enoxaparin and unfractionated heparin on Tissue Factor Pathway Inhibitor (TFPI) release and prothrombinase activity inhibition in whole blood in 12 healthy volunteers (1992) (0)
90326019 Relationship between plasminogen activator inhibitor activity and menopausal status (1991) (0)
[Biological monitoring and prevention of complications from antithrombotic agents]. (1996) (0)
REFLEX SYMPATHETIC ACTIVATION PROVOKED BY DIHYDROPERIDINE CALCIUM CHANNEL BLOCKERS EXISTS DURING FENTANYL-BENZ0DIAZEPINE-N20 ANESTHESIA (1988) (0)
[Long-term antithrombotic treatment in coronary disease]. (1983) (0)
Prophylaxis for venous thrombosis in medical and surgical patients (2006) (0)
Congenital protein Cdeficiency andthrombotic disease in nineFrench families (1984) (0)
Prothrombin time assay for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicentre field trial (2012) (0)
Thromboembolism: New Insights and Future Prospects: 7th International Symposium on Thromboembolic Diseases, Palma de Mallorca, June 2000: Proceedings (2001) (0)
[Constitutional protein C deficiency in 57 patients from 22 non-related families]. (1986) (0)
Initial Phase of Hemostasis (2019) (0)
[Current problems in thrombolytic treatments]. (1968) (0)
Title Page / Table of Contents, Vol. 26, Supplement 2, 1996 (1996) (0)
[Study of the inhibition of blood platelet aggregation and adhesiveness by 2 soluble derivatives of acetylsalicylic acid]. (1975) (0)
[The place of Owren's thrombotest in the control of anticoagulant treatment]. (1962) (0)
Platelet Volume Distribution in Primary and Secondary Thrombocytopenias (1977) (0)
[Analysis of fibrinolytic activity by the Fearnley test]. (1966) (0)
[Anistreplase. Pharmacology and biological data]. (1990) (0)
Prevention ofdeepveinthrombosis after hipreplacement: randomised comparison between unfractionated heparin andlow molecular weight heparin (1991) (0)
Pathogenesis of Thrombosis (2019) (0)
Effect of weight reduction on fibrinolysis in obese patients (1994) (0)
Congenital thrombophilia: facts and controversies (1990) (0)
[New thrombolytic agents in myocardial infarction]. (1999) (0)
Miscellaneous: Dextran, Dermatan Sulfate, Low Molecular Weight Heparinoids (Org 10172), Pentosan Polysulfate (Sp54), Defibrinating Agents (Ancrod And Reptilase) (2019) (0)
PSEUDO-THROMBOCYTOPENIA ASSOCIATED WITH AN ANTICOAGULANT INDEPENDENT IgM PLATELET AGGLUTININ IN A PATIENT WITH PROLONGED BLEEDING TIME (1987) (0)
[Low molecular weight heparins in everyday practice]. (1991) (0)
THE ROLE OF A 3-0 SULFO GROUP IN THE GLUCOSAMINE RESIDUE OF A SYNTHETIC OLIGOSACCHARIDE FOR THE DETERMINATION OF ANTITHROMBOTIC ACTIONS (1987) (0)
Congenital Deficiency of Antithrombin III and of Heparin Cofactor II (2019) (0)
[Biological monitoring of antithrombosis treatments (author's transl)]. (1981) (0)
Welcome Address by Prof. A. Serradimigni (1986) (0)
[Medical treatment of deep vein leg thrombosis with medications other than heparin]. (1978) (0)
[On platelet adhesiveness and aggregation in diabetics treated with linoleic acid]. (1966) (0)
[Present-day agents of antifibrinolytic therapy]. (1962) (0)
[Use of injectable warfarin in thrombopenia related to heparin]. (1987) (0)
[Coagulopathy in severe sepsis: is there anything new?]. (2003) (0)
[Determination of plasma plasminogen by the study of fibrinolysis in the presence of Kunitź inhibitor]. (1966) (0)
Use of antidotes inhibitors indicated coagulation in the prevention or treatment of thromboembolic pathologies (2013) (0)
Circulating Platelet-Leukocyte Aggregates as a Marker of Microvascular Lesions in Diabetic Patients. (2005) (0)
[Long transfusion series in certain severe episodes of hemophilia A]. (1962) (0)
Thrombolytic therapy in myocardial infarction: Are fibrinolytic drugs comparable, and similarly effective? (1985) (0)
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]. (2004) (0)
[Systematic study of hemostasis disorders in 20 partial hepatectomies]. (1977) (0)
[Skin necrosis during long-term fluindione treatment revealing protein C deficiency]. (2012) (0)
[THROMBOLYTIC THERAPY. TRIAL TREATMENT WITH PURIFIED STREPTOKINASE]. (1964) (0)
[3 observations on the use of factor 8 enriched plasma fractions in surgery on subjects with hemophilia A]. (1966) (0)
Protein C (1986) (0)
[Thrombolytic treatment in the acute phase of myocardial infarction. Evaluation in 1986]. (1986) (0)
[A new cause of hereditary thrombophilia: activated protein c resistance]. (1994) (0)
[Synthetic compounds with fibrinolytic and thrombolytic activity. 2. Studies on mode of action]. (1976) (0)
[Can one treat intravascular thromboses with thrombolytics without risk?]. (1968) (0)
[Diagnosis of defibrinations]. (1972) (0)
[Thromolytic treatment by streptokinase of arterial embolism of the extremities]. (1968) (0)
[Direct tests of exploration of the thrombodynamic function of the platelets]. (1961) (0)
LA PREVENTION DU RISQUE THROMBOTIQUE EN CHIRURGIE ORTHOPEDIQUE EST INDISPENSABLE (1998) (0)
[Thrombophotography of the coagulation of non-diluted human plasma]. (1968) (0)
[THROMBODYNAMOGRAPHIC PLATELET QUALITATIVE TESTS. CLINICAL AND BIOLOGICAL SIGNIFICANCE IN THROMBOPENIA]. (1963) (0)
Subject Index, Vol. 13, 1983 (1983) (0)
[Value of carbon in the thrombogenicity of cardiovascular prostheses]. (1997) (0)
Comparison of the effficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis : An updated meta-analysis. Discussion (1996) (0)
[Theoretical bases for the use of anticoagulants and thrombolytic agents]. (1979) (0)
[Presence of a plasma antigen indispensable to the stabilization of fibrin in 2 cases on congenital factor XIII deficiency]. (1970) (0)
Low dose heparin in gynaecological surgery: effect on blood coagulation tests. (2009) (0)
Low-Molecular-Weight Heparin: A New Therapeutic Approach to Thrombosis: Seville, Spain, October 1994: Proceedings (1996) (0)
[Congenital dysfibrinogenemia. Apropos of 13 cases]. (1983) (0)
[Gastrectomy in a patient presenting a moderate hypoproconvertinemia]. (1968) (0)
[Action of anti-platelet immune antibodies on the thromboelastogram]. (1959) (0)
[Extracorporeal circulation and consumption coagulation disorders]. (1967) (0)
[Apropos of a case of Glanzmann's thrombasthenia. Clinical and biological study]. (1966) (0)
Laboratory assessment of hemorrhagic diathesis (2002) (0)
[Measurement of platelet volume: methodologic approach and application in diabetes]. (1982) (0)
[Severe hemorrhagic complications during treatment with low molecular weight heparin. Apropos of 2 cases]. (1997) (0)
[Some recent advances in the anticoagulant and fibrinolytic therapy of thrombosis]. (1967) (0)
Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma. (2010) (0)
Laboratory Diagnosis Of Acquired Thrombophilic States: Detection of Markers of Activation of Primary Hemostasis and of Blood Coagulation (2019) (0)
[Platelet kinetics and diameter in heart valve diseases]. (1981) (0)
[FIBRINOLYSIS AND EPSILON-AMINOCAPROIC ACIDS]. (1964) (0)
[Estro-progestatives and coagulation] (1970) (0)
Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
, Calibrators and Controls : Results of a Multicenter Field Trial Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using (2012) (0)
Homozygous protein C deficiency in 3 unrelated adults (1992) (0)
[Combination of antibiotics & corticoids in severe forms of infectious diseases in children]. (1957) (0)
[The place of bleeding time in the current exploration of thrombopenia]. (1963) (0)
[Diagnosis of defibrination syndromes in infectious pathology]. (1984) (0)
[Quantitative determination of Willebrand factor activity in Willebrand's disease]. (1976) (0)
Contents Vol. 32, 2002 (2002) (0)
Conclusion (2001) (0)
[Once upon a time there was hirudin...]. (1998) (0)
[Platelet count and distribution of platelet volume in whole blood using a Coulter S Plus. Demonstration of errors not detected by the apparatus]. (1984) (0)
Ticlopidine and Platelet Function (1986) (0)
[Anticoagulant treatment by warfarin sodium in cardiology. Apropos of 63 cases (2710 days of treatment)]. (1960) (0)
Protease inhibitors : proceedings of the Second International Conference on Fibrinolysis, Hamamatsu, Japan, 26 August 1989 (1990) (0)
Low Molecular Weight Heparin and Its Clinical Use: International Enoxaparin Symposium, San Diego, Calif., July 1985 (1986) (0)
[Changes in platelet aggregation during treatment with acetylsalicylic acid. Sensitivity of various aggregating agents]. (1982) (0)
[BIOLOGICAL SURVEILLANCE OF THROMBOLYTIC TREATMENT]. (1963) (0)
Tnf effect on u pa and pai 1 production by the a549 lung carcinoma cell line treatment of monolayer and tridimensional cultures (1990) (0)
[B-cell lymphoma and low aggressiveness: from the historical paradigm of a clinico-biological entity to the challenge of an effective therapeutic strategy]. (1964) (0)
[Severe hypoproconvertinemia and extracorporeal circulation for mitral valve replacement]. (1982) (0)
Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study (2008) (0)
[Congenital deficiency of factor XI: diagnosis and therapy in surgical patients (author's transl)]. (1980) (0)
[Importance of thromboelastography (thrombodynamography) in the control of treatments of myocardial infarct with anticoagulants]. (1960) (0)
[Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa]. (2003) (0)
[The paradox of thrombin]. (1996) (0)
Comparison of recombinant hirudin (HBW 023) and standard heparin in preventing thrombus formation in a Wessler model (1990) (0)
[Erythrocyte aggregation and clinical course stages of venous insufficiency of the legs]. (1992) (0)
Proceedings of the third International Conference on Synthetic Fibrinolytic Agents (1978) (0)
[Rosenthal's disease (deficiency in factor XI). Apropos of a case operated for breast cancer]. (1968) (0)
Streptokinase and APSAC inhibit the platelet aggregation in vitro by fibrinogenolysis: Effect of fibrinogen degradation products X and E generated in plasma (1994) (0)
Effect of Agents which Modify Platelet Aggregation and/or Coagulation on Experimental Platelet Embolism and Intravascular Coagulation (1977) (0)
Antithrombotic therapy for venous thromboembolic disease. (2001) (0)
Human anti-streptokinase antibodies induce platelet aggregation in a Fc/CD32-dependent manner (1994) (0)
[Mechanisms of venous thrombosis. Therapeutic deductions on prophyloxis]. (1977) (0)
Assessment of primary haemostasis in intensive care patients: a study using the PFA 100® (2000) (0)
[STUDY OF CHANGES IN BLOOD COAGULATION IN THE COURSE OF MASSIVE SCLEROSING TREATMENTS]. (1965) (0)
[Streptokinase treatment of acute vascular obliterations]. (1968) (0)
[Hirudin and hirudin fragments]. (1992) (0)
Fibrinolysis and Thrombosis: Pathways and Inhibitors (1981) (0)
[Apropos of a fatal case of thrombopenic purpura in the course of a cyanotic congenital cardiopathy]. (1962) (0)
[Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)]. (1985) (0)
Title Page / Contents / Preface (1999) (0)
[Thoughts on coagulation time]. (1965) (0)
Detection of lupus anticoagulants (1995) (0)
[Thrombo-dynamography in the study of inhibitors of coagulation]. (1959) (0)
[Treatment of an acute fibrinolytic complication with a new antiproteolytic agent during a portacaval anastomosis]. (1961) (0)
[Experimental arterial thrombosis. In vivo and in the vitro effects of aspirin and prostaglandin E1]. (1972) (0)
[Surgery in hemophilia. Nephrectomy without hemorrhagic difficulties]. (1965) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
Familial And Constitutional Moderate Bleeding Disorder Associated With Defective Platelet Cyclo-Oxygenase (1981) (0)
82 Analysis of fibrinogenolysis degradation products induced by streptokinase (SK) or recombinant tissue plasminogen activator (rt-PA) (1988) (0)
[Conditions of resistance to vitamin K antagonists]. (1964) (0)
[Owren's thrombo-test]. (1960) (0)
90071416 Factor VII activation and menopausal status (1990) (0)
Dosage de l’apixaban – variabilité interindividuelle (2014) (0)
[On two cases of fibrinolysis in the course of cancers of the prostate with osseous metastases]. (1959) (0)
[Hemorrhagic complications of fibrinolysis]. (1962) (0)
[Lipids and thrombosis. Experimental and clinical achievements]. (1980) (0)
133 Low molecular weight and standard heparin stimulate plasminogenolytic activity of ProUK (1988) (0)
Prevention of Postthrombotic Syndrome (2013) (0)
[Value & limitation of thromboelastography in supervision of anticoagulant treatment in cardiology]. (1958) (0)
[Biological technics of supervision of anticoagulant treatment]. (1962) (0)
Subject Index Vol. 2, 1973/74 (1973) (0)
[Hemorrhagic disease of the newborn, with blood incoagulability]. (1966) (0)
DDE COMPLEX DETERMINATION AS A SPECIFIC MARKER FOR FIBRINOLYSIS (1987) (0)
[Acute arterial obliteration. Thrombolysis with streptokinase. Cure]. (1964) (0)
Urologic Surgery (2013) (0)
[Cortisone & pericardial or pleural tuberculosis with pulmonary lymph node localization]. (1957) (0)
[Actilyse: biological aspects]. (1988) (0)
Thromboembolic diseases: mechanisms, prophylaxis and treatment. Concluding remarks. (1998) (0)
DISSOCIATION BETWEEN DDE LEVEL AND RECANALIZATION IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION. A POSSIBLE EXPLANATION (1987) (0)
Panel Discussion (2012) (0)
[Characteristics of the diagnosis and treatment of venous thrombosis. Benefit-risk relationship of anticoagulant treatment]. (1995) (0)
[The anti-platelet agents in 1987]. (1987) (0)
[The detection of soluble fibrin complexes by a haemagglutination test. Clinical applications (author's transl)]. (1977) (0)
Red blood cell aggregation in smokers (1995) (0)
Abstract P230: Risk of Venous Thromboembolism in Acutely Ill Medical Patients and the Influence of Timely Ambulation (2011) (0)
Constitutional protein c deficiencies study of 8 families (1984) (0)
[The eccentriplate device on the Dideco Vivacell cell separator for the collection of platelets]. (1988) (0)
[Value of the platelet count using electronic counter]. (1970) (0)
In Vitro Effect of Danaparoid Sodium (Orgaran®) on Thrombin Generation after Minimal Tissue Factor Pathway Activation. (2005) (0)
Title Page / Table of Contents, Vol. 23, Supplement 1, 1993 (1993) (0)
[Prevention of thrombo-embolic venous disease]. (2003) (0)
Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
Constitutional Thrombocytopathia with Abnormal Aggregation Different from Storage-Pool Disease and Aspirin-Like Syndrome (1977) (0)
Title Page / Table of Contents / Preface (2003) (0)
C0295 Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery. An observational study (2012) (0)
[THE PHYSIOPATHOLOGY OF FIBRINOLYSIS AND ITS CLINICAL AND THERAPEUTIC APPLICATIONS]. (1964) (0)
[Value of the platelet count using electronic counter]. (1970) (0)
concentrations and risk of myocardial infarction. The ECTIM Study Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen (2011) (0)
[Safety of donors, quality of products, how much to reduce the quantity of citrate]. (1991) (0)
Endogenous Thrombin Potential (ETP) in Patients with Hereditary Antithrombin (AT) Deficiency or Carriers of the Prothrombin (PT) 20210A Gene Mutation. (2007) (0)
[Thrombolytic treatments]. (1972) (0)
A New Inhibitor of Factor XIII and Platelet Aggregation. Influence of Fibrin Stabilization on Thrombolysis (1979) (0)
[Activated protein C resistance and mutation of coagulation factor V]. (1996) (0)
[Where to look for progress in antithrombotic treatments?]. (1999) (0)
[Elements of choice of thrombolytic agents in myocardial infarction]. (1992) (0)
Errors in platelet counts. (1982) (0)
Symposium on low molecular weight heparins (LMW heparins) (1996) (0)
[Results isoniazid treatment of meningeal tuberculosis in Charles Nicolle Hospital]. (1956) (0)
[Biological markers for acute phase hemostasis in coronary thrombosis]. (2002) (0)
Thromboembolic Diseases: Mechanisms, Prophylaxis and Treatment: 5th International Symposium, Cannes, June 1998 (1998) (0)
The Effect of Irreversible and Reversible Direct Thrombin Inhibitors and Danaparoid on Tissue Factor Mediated Thrombin Generation. (2006) (0)
Does neuromuscular blockade require for laparoscopic gastroplasty?: A-133 (2005) (0)
[Fibrin stabilizing factor of placental origin. Physicochemical and immunochemical studies. Biological role]. (1974) (0)
[Massive pulmonary embolism during bacillary tuberculous pneumonia. Remarkable effects of streptokinase]. (1973) (0)
[Thrombolytic medications]. (1965) (0)
[CURRENT RESULTS OF THE USE OF PURIFIED STREPTOKINASE. (APROPOS OF 19 CASES)]. (1963) (0)
Thromboembolic diseases : mechanisms, prophylaxis and treatment, proceedings 5th international symposium on thromboembolic diseases, Cannes, June 12-13, 1998 (1998) (0)
[Applications of simultaneous thrombodynamography (thromboelastography) of plasma rich in platelets (P.R.P.) and of plasma without platelets (P.D.P.) to the problem of thromboses and of their treatment with anticoagulants]. (1961) (0)
[Current place of anticoagulants, fibrinolytic and anti-aggregation agents in the prevention of thrombosis]. (1973) (0)
Thromboembolism: New Achievements and Challenges: 6th International Symposium on Thromboembolic Diseases, Lisbon, June 1999: Proceedings (1999) (0)
[Biologic control of long-term anti-coagulating therapy with antivitamins K]. (1967) (0)
[Biologic data furnished by the experience of thrombolytic treatments with streptokinase]. (1968) (0)
[Study of the bleeding mechanism during fibrinolysis induced by streptokinase in the rabbit (author's transl)]. (1977) (0)
[Study of hemostasis in patients with a recent thromboembolic complication]. (1995) (0)
[Acute defibrination without fibrinolysis associated with postabortum septicemia. Clinical and biologic study]. (1968) (0)
[Not Available]. (1959) (0)
[Effect of flurbiprofen on platelet functions. Study of its interference with the synthesis of platelet thromboxane and production of prostacyclin by the rabbit aorta]. (1983) (0)
[Influence of saturated and unsaturated fatty acids on the filtration pressure and aggregation of platelets]. (1973) (0)
[Acute fibrinolysis disclosing cancer of the prostate with bone metastases. Efficacy of epsilon-aminocaproic acid]. (1963) (0)
[Thombogenicity of biomaterials in cardiovascular surgery. Thrombo-protection and different types of grafts]. (1997) (0)
[The effect of saturated and non-saturated fatty acids on the filtration pressure of platelet-rich plasma. Correlation with platelet aggregation]. (1973) (0)
Severe Acquired Deficiency of Vitamin K-Dependent Factors and Resistance to Multiple Vitamin K Injections (1989) (0)
[Platelet aggregation and von Willebrand's factor in 32 insulin-dependent diabetics. Value of the measurement of filtration pressure in the presence of ADP]. (1976) (0)
Platelets and Heparin Induced Thrombocytopenia Antibodies Do Not Influence the Inhibitory Activity of Argatroban on Thrombin Generation. (2007) (0)
[Importance of blood coagulation time in silicone-treated tubes in the control of anticoagulant treatment in cardiology]. (1959) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Meyer‐michel Samama?

Meyer‐michel Samama is affiliated with the following schools:

University of Ferrara

Meyer‐michel Samama's Academic­Influence.com Rankings

Why Is Meyer‐michel Samama Influential?

Meyer‐michel Samama's Published Works

Published Works

What Schools Are Affiliated With Meyer‐michel Samama?

Meyer‐michel Samama's AcademicInfluence.com Rankings